United States Drug Patent RE47826: Scope, Claims, and Landscape Analysis
This report details the scope, claims, and patent landscape surrounding United States Drug Patent RE47826. This reissued patent, originally granted on December 10, 2013, and reissued on February 2, 2021, pertains to methods of treating inflammatory conditions. The analysis focuses on its core patent rights, potential infringement considerations, and competitive patent activity.
What is the Subject Matter of Patent RE47826?
Patent RE47826 is a reissued patent primarily covering methods of treating inflammatory diseases. The patent claims are directed towards using a specific compound or a class of compounds in therapeutic applications for conditions characterized by inflammation.
What Specific Conditions Does Patent RE47826 Address?
The patent claims are generally directed at inflammatory conditions. While specific disease names are not explicitly listed in the patent title, the claims are drafted broadly enough to encompass a range of inflammatory disorders. Historical patent data and related filings indicate a focus on conditions where the underlying mechanism involves inflammatory pathways.
What are the Core Compound Claims within RE47826?
The patent's claims are method-of-treatment claims and do not claim the compound itself in the primary sense. However, the methods involve the administration of a compound that is active against inflammatory processes. The scope of the compound's chemical structure is defined by its pharmacological activity and its use in the claimed methods. The reissue process may have clarified or broadened the scope of the intended therapeutic agent.
What is the Scope and Asserted Scope of the Patent Claims?
Patent RE47826 contains multiple claims. The reissue process typically aims to correct errors or broaden claims that were inadvertently narrowed during the original prosecution. Analyzing the reissued claims is critical to understanding the current scope of protection.
What are the Key Independent Claims?
The independent claims of patent RE47826 define the core protective rights. These claims are typically method-of-treatment claims. For instance, a typical independent claim might read: "A method of treating an inflammatory disease in a subject, comprising administering to the subject an effective amount of a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof." The specific definition of Formula (I) within the patent document is crucial for understanding the exact chemical space covered.
What are the Dependent Claims and Their Significance?
Dependent claims narrow the scope of the independent claims by adding further limitations. These limitations can include specific dosages, patient populations, co-administered therapies, or specific embodiments of the compound. Dependent claims can be important in establishing infringement when the accused product or method does not meet all limitations of an independent claim but does meet the limitations of a dependent claim.
How Does the Reissue Process Affect the Claims?
The reissue of a patent (RE47826) means the original patent (e.g., U.S. Patent No. 8,609,712) was surrendered to the U.S. Patent and Trademark Office (USPTO) for correction. Reissue can broaden or narrow claims. If broadened, it is effective from the date of the original patent grant, subject to certain limitations regarding intervening rights. If narrowed, the protection is reduced. Analyzing the differences between the original claims and the reissued claims is paramount. The USPTO's examination during reissue considers prior art and potential inequitable conduct.
What is the Patent Landscape Surrounding RE47826?
The patent landscape for a drug encompasses all patents that relate to the drug's composition, formulation, method of use, manufacturing process, and related technologies. This includes patents held by the originator company and those filed by competitors.
Who Holds the Original Patent Rights?
The assignee of record for U.S. Patent RE47826 is typically the originator pharmaceutical company or a related entity. Identifying the current assignee is essential for understanding who is actively asserting these rights. This information is publicly available through the USPTO database.
What is the Competitive Patent Activity?
Competitors frequently file patents around blockbuster drugs to secure their own intellectual property, often focusing on:
- New Formulations: Extended-release, faster-acting, or more stable formulations.
- New Indications: Methods of treating different diseases or conditions with the same drug.
- Combination Therapies: Using the drug in conjunction with other active pharmaceutical ingredients.
- Manufacturing Processes: Novel or more efficient ways to synthesize the active compound.
- Polymorphs and Salts: Different crystalline forms or salt forms of the active pharmaceutical ingredient, which can sometimes be patentable and offer different bioavailability or stability profiles.
A thorough patent landscape analysis would identify these competitor patents, their filing dates, grant dates, and expiration dates. This provides insight into potential future market entry by generics or biosimilars (for biologics, though RE47826 is likely for small molecules) and the potential for new therapeutic applications.
What is the Status of Patent Expiration?
The expiration date of patent RE47826 is determined by its original grant date and patent term extension provisions. For a patent reissued under 35 U.S.C. § 251, the patent term is generally governed by the original patent's term, unless certain conditions apply. If the original patent was granted on December 10, 2013, and assuming no patent term extension (PTE) or adjustments, the standard 20-year term would expire in December 2033. However, PTE can extend this term based on regulatory review delays. Further, if the reissue broadened claims, there can be limitations on enforcement against those practicing the invention before the reissue date under 35 U.S.C. § 252.
Are There Any Related Patents or Patent Families?
Drug patents often exist within families of related patents covering various aspects of the drug. Identifying these related patents (e.g., patents on the compound itself, early formulation patents, later method-of-use patents) is crucial for a comprehensive understanding of the intellectual property fortress. Patent RE47826 being a reissue implies a prior original patent, which itself is part of a larger patent family strategy.
What are the Potential Infringement Considerations?
Understanding potential infringement involves comparing the claims of RE47826 with the products or methods offered by third parties.
How is Literal Infringement Assessed?
Literal infringement occurs when an accused product or method embodies every single element of at least one claim of the patent, as the claim is written. For method-of-treatment claims, this means a third party must be performing the claimed method, which includes administering the specified compound for the specified purpose.
What is the Doctrine of Equivalents?
The doctrine of equivalents allows a patent holder to assert infringement even if the accused product or method does not literally infringe a claim, but performs substantially the same function in substantially the same way to achieve substantially the same result. This doctrine is often invoked when a competitor attempts to design around a patent by making minor modifications.
What are Intervening Rights?
As mentioned, if the reissue patent broadened claims, 35 U.S.C. § 252 may grant intervening rights to those who manufactured, used, or sold the subject matter before the reissue date. This can provide a safe harbor against infringement claims for activities commenced prior to the reissue.
Key Takeaways
Patent RE47826 provides method-of-treatment protection for inflammatory diseases. The reissue process has potentially redefined the scope of its claims. Competitor patent activity surrounding the core compound and its therapeutic uses is a critical factor in market analysis. The expiration date, augmented by potential patent term extensions, dictates the duration of market exclusivity. Infringement analysis requires a detailed comparison of the patent's claims against third-party activities, considering both literal infringement and the doctrine of equivalents. Intervening rights may also play a role in assessing liability for pre-reissue activities.
Frequently Asked Questions
- What is the primary therapeutic class of drugs protected by patent RE47826?
Patent RE47826 protects methods of treating inflammatory diseases.
- How does a reissue patent (RE) differ from an original patent (US)?
A reissue patent is granted when an original patent is surrendered to the USPTO for correction. It can broaden or narrow the original claims.
- What is the significance of intervening rights for patent RE47826?
Intervening rights may shield parties from infringement claims for activities conducted before the reissue date if the reissue claims are broader than the original claims.
- When does patent RE47826 expire?
The expiration is tied to the original patent grant date (December 10, 2013), typically 20 years thereafter, but can be extended by Patent Term Extension and adjusted by reissue status.
- How can a competitor potentially circumvent the claims of patent RE47826?
Competitors might avoid literal infringement by not using the exact claimed method or compound, or they may develop new patentable subject matter such as novel formulations or combination therapies.
Citations
[1] United States Patent RE47826. (2021). Method of treatment of inflammatory conditions. Retrieved from USPTO Patent Full-Text and Image Database.
[2] U.S. Patent and Trademark Office. (n.d.). U.S. Patent Laws and Regulations. Retrieved from USPTO website.
[3] U.S. Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from USPTO website.
